EAM
PRAX icon

Exome Asset Management’s Praxis Precision Medicines PRAX Stock Holding History

Exome Asset Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$530K – 81
2025
Q3 		$530K Buy
+10,000
New +$485K 0.32% 59

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Exome Asset Management's PRAX Position: Q1 2026 in Review

Exome Asset Management reduced its Praxis Precision Medicines (PRAX) stake by 22% in Q1 2026, selling an estimated $3.91M and leaving 45,469 shares worth $14.6M. The position accounts for 7.58% of the portfolio, ranked #1.

Exome Asset Management first reported a position in PRAX in Q2 2025 and has held it in 4 quarters since. The position peaked at $17.1M in Q4 2025. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Exome Asset Management held 45,469 shares of Praxis Precision Medicines worth $14.6M as of Q1 2026.
  • Exome Asset Management sold 12,653 Praxis Precision Medicines shares in Q1 2026, an estimated $3.91M.
  • Praxis Precision Medicines made up 7.58% of Exome Asset Management's portfolio in Q1 2026, its #1 holding.
  • Exome Asset Management first reported a position in Praxis Precision Medicines in Q2 2025 and has held it in 4 quarters since.
  • Exome Asset Management's Praxis Precision Medicines position peaked at $17.1M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.